| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99233 |
Prolong inpt eval add15 m |
1,823 |
1,017 |
$156K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
396 |
187 |
$82K |
| 99472 |
Subsequent inpatient pediatric critical care, per day, 2-5 years |
193 |
67 |
$71K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
300 |
299 |
$21K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
442 |
439 |
$19K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
131 |
130 |
$13K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
80 |
80 |
$8K |
| 99232 |
Subsequent hospital care, per day, moderate complexity |
138 |
87 |
$7K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
31 |
31 |
$5K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
35 |
35 |
$4K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
30 |
30 |
$3K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
25 |
25 |
$3K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
48 |
48 |
$1K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
19 |
19 |
$1K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
12 |
12 |
$859.68 |
| 90461 |
|
25 |
25 |
$577.27 |
| 96127 |
|
36 |
36 |
$187.92 |
| 96160 |
|
36 |
36 |
$163.95 |
| 90686 |
|
113 |
113 |
$0.00 |
| 90685 |
|
26 |
26 |
$0.00 |